Navigation Links
Noscira Presents Results of Phase IIa Clinical Trial with Nypta(R) (Tideglusib) on Alzheimer's Disease at International Conference on Alzheimer's Disease (ICAD)
Date:7/15/2010

treatment was well tolerated. The drug was also observed to have a positive effect on patients' cognitive performance, though this is not statistically significant due to the small sample size and short treatment period.

Nevertheless, the following findings are indicative of therapeutic benefit:

  • Patients treated with Nypta(R) (Tideglusib) in addition to an acetylcholinesterase inhibitor as base treatment showed a consistent improvement in four of the five clinical efficacy variables that were assessed: Mini Mental State Examination (MMSE), Alzheimer's Disease Assessment Scale (ADAS-cog), Geriatric Depression State and Global Clinical Assessment. Those variables are cognitive-behavioral scales for confirming and quantifying a person's mental state.
  • The improvement was more appreciable in the patients who attained the highest dose: they improved in the MMSE and ADAS-cog cognitive scales, the effect being greater than when using cholinesterase inhibitors alone.
  • Moreover, the number of patients that showed stabilization or improvement in the MMSE scale was significantly greater in the group treated with Nypta(R) (Tideglusib).

About Zeltia:

Zeltia S.A. is a world-leading biopharmaceutical company specialized in the development of marine-based drugs for use in oncology and central nervous system illnesses. Grupo Zeltia consists mainly of the following companies: PharmaMar, a biotechnology company that is the world leader in advancing cancer care through the discovery and development of innovative marine-derived medicines; Noscira, a biotech firm focused on discovering and developing new drugs against Alzheimer's disease and other neurodegenerative diseases of the central nervous system; Genomica, Spain's leading molecular diagnosti
'/>"/>

SOURCE Group Zeltia
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
3. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
4. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
5. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
6. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
7. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
8. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
9. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
10. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
11. Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... -- CryoLife, Inc. (NYSE: CRY ), a leading ... and vascular surgery, announced today that James Patrick ... been elected to the Company,s Board of Directors, effective ... , Executive Chairman of CryoLife, stated, "Since joining the Company ... leader who is well positioned to maximize CryoLife,s potential. ...
(Date:10/22/2014)... 21, 2014  Early symptoms of diabetic eye ... but new technology, coupled with yearly, comprehensive eye ... earlier detection of eye diseases, including those associated ... If left untreated, these diseases can potentially lead ... Recently, optometric researchers have deployed a new ...
(Date:10/22/2014)... -- InVivo Therapeutics Holdings Corp. (OTCQB: NVIV) based in ... cord injury (SCI) treatment with their novel Neuro-Spinal Scaffold. ... regrowth in the spinal cord area when cells are ... polymer, the scaffold ultimately breaks down to water and ... NVIV has recently attracted significant investor attention with the ...
Breaking Medicine Technology:Pat Mackin Joins CryoLife Board of Directors 2Pat Mackin Joins CryoLife Board of Directors 3Technology Advancements Enhance Early Detection of Eye Diseases Associated with Diabetes 2Technology Advancements Enhance Early Detection of Eye Diseases Associated with Diabetes 3InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 2InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 3
(Date:10/22/2014)... Lexington, Kentucky (PRWEB) October 22, 2014 ... an agreement that will change the current location of ... Road to South Limestone across from the University of ... be a state-of-the-art ambulatory care center, owned and operated ... meet the orthopaedic needs of children and their families ...
(Date:10/22/2014)... With the Affordable Care Act (ACA) open enrollment ... Institutes for Research (AIR) finds that three out of four ... but 42 percent say they are not likely or only ... for coverage. , The AIR survey found wide gaps in ... calculate correctly how much they owe for a routine doctor’s ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 Healthcare ... completing their continuing education at home or on-the-go ... access to 20 brand new, premium Seminar-on-Demand CE ... catalog of over 2,000 hours of ... customize their educational experience. With such a diverse ...
(Date:10/22/2014)... Mission Viejo, CA (PRWEB) October 22, 2014 ... that Jay Cormier, Sr. Vice President of Sales, will ... at the upcoming Meetings Technology Expo on October 28, ... will also be hosting a booth as well as ... on how Lintelus Meeting can create a more engaging ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, ... length may be showing a genetic propensity for obesity as ... have been linked to increased body fat, but the same ... muscle, the researchers said. At 1 year, kids with ... and 3, however, these genes were linked to excessive weight ...
Breaking Medicine News(10 mins):Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 2Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 2Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 4Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2Health News:Tall, Heavy 1-Year-Olds May Be at Risk for Obesity Later, Study Finds 2
... study conducted by researchers say it is a misconception ... older or housebound people.// ,Researchers examined 150 ... levels of vitamin D. Among the participants, all African-American, ... D deficiencies, as were all patients younger than 30. ...
... A pitch-black room may be the healthiest environment for your ... at night // may put children at risk for ... to disrupt the circadian rhythm and suppress the production of ... been shown to protect DNA from oxidative damage. Once damaged, ...
... study shows sinusitis in asthma patients tends to be ... suggest patients // can have dramatic improvement in symptoms ... is used. ,In the study patients with asthma ... polyps, olfactory dysfunction, and nasal congestion compared to patients ...
... new study shows moderate consumption of alcohol may cut ... arteries.// Researchers evaluated 225 men after they had undergone ... open blocked arteries with a stent. Less traumatic than ... cause inflammation resulting in renarrowing of the artery, usually ...
... study researchers say the antidepressant duloxetine, also known ... fibromyalgia in women . Duloxetine works by stopping ... of the brain’s neurotransmitters that are linked to ... that is characterized by body pain, muscle tenderness, ...
... cluster of risk factors known as metabolic syndrome is ... risk factors. // ,Metabolic syndrome has been ... coronary heart disease. Metabolic syndrome includes looking at factors ... has two different definitions including one by the National ...
Cached Medicine News:
... multichannel pipettes speed up ... into microplates, with super ... volumes. The improved ergonomic ... multichannels, combined with super ...
... Hamilton is precision, ergonomics, and value!, ... with soft non-slip, contoured handle , Finer ... spring action , Stress-free tip ejection with ... for easy decontamination and sterilization without the ...
... The Finnpipette Digital Multichannel, with ... lighter work of routine laboratory ... these advanced features: Soft-touch tip ... volume pipetting (0.5-10ul models), Entire ...
... Research pro Electronic Pipette is ideal for ... Its easy-to-follow display, ergonomically-placed operating buttons, and ... reverse pipetting and diluting make this a ... functions of a manual pipette without any ...
Medicine Products: